Oppenheimer analyst Trevor Allred raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $145.00 (from $125.00) while maintaining a Outperform rating.

The analyst comments "Dianthus shares are trading up ~28% vs the XBI's ~0.7%. Today's CIDP "Go" decision came earlier than expected, with >20 responders despite <40 enrolled patients, suggesting potentially superior results to riliprubart's Phase 2 outcome despite incrementally higher SoC-refractory patients enrolled. Safety appears unremarkable, with no symptoms of autoimmune activation, no discontinuations due to study drug, and no infections of concern. Management plans to drop the 600mg arm and cut Part B enrollment to 128 (from 192). Despite lower enrollment, management expects study may be powered better than previously anticipated. These results reaffirm our comfort with potential best-in-class efficacy and likely further accelerate trial timelines."